Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.51 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4141214 | 0.92 | PLA2G2A (0.59) | PLA2G2ATHRATHRBPLA2G4B | |
| SCHEMBL12431968 | 0.91 | PLA2G2A (0.62) | PLA2G2APLA2G4B | |
| SCHEMBL11435088 | 0.91 | PLA2G2A (0.62) | PLA2G2APLA2G4B | |
| SCHEMBL38650624 | 0.91 | PLA2G2A (0.62) | PLA2G2APLA2G4B | |
| SCHEMBL12431955 | 0.90 | PLA2G2A (0.59) | PLA2G2APLA2G4B | |
| SCHEMBL25788081 | 0.88 | PLA2G2A (0.66) | PLA2G2ATHRATHRBPLA2G4B | |
| SCHEMBL2358713 | 0.88 | PLA2G2A (0.66) | PLA2G2ATHRATHRBPLA2G4B | |
| SCHEMBL8644661 | 0.88 | PLA2G2A (0.66) | PLA2G2ATHRATHRBPLA2G4B | |
| SCHEMBL26581106 | 0.86 | TPMT (0.50) | — | |
| SCHEMBL16645345 | 0.85 | PLA2G2A (0.50) | PLA2G2ATHRATHRBPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846366-B1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-1846366-B1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-7718703-B2 | Norvaline derivative and method for preparation thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1846366-A1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006080477-A1 | NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076769-A1 | Norvaline Derivative and Method for Preparation Thereof | SLC38A7, SLC7A1, SLC6A7 | PLA2G2A 3858/4885THRA 1548/4885THRB 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.